Society on Sarcopenia, Cachexia and Wasting Disorders

Biophytis reports clinical results for Sarconeos (BIO101) in sarcopenia treatment at the 16th SCWD International Congress

Retrieved on: 
Monday, June 19, 2023
Society, Euronext Growth, SARA, CET, Therapy, Cachexia, Society on Sarcopenia, Cachexia and Wasting Disorders, Ageing, Research, Doctor of Philosophy, EMA, Patient, FDA, Notifiable disease, Pharmaceutical industry, Neuroscience, Sarcopenia

Biophytis has given an oral presentation entitled "BIOPHYTIS BIO101 - a candidate treatment for muscle diseases" on the development of Sarconeos (BIO101) for the treatment of sarcopenia.

Key Points: 
  • Biophytis has given an oral presentation entitled "BIOPHYTIS BIO101 - a candidate treatment for muscle diseases" on the development of Sarconeos (BIO101) for the treatment of sarcopenia.
  • It was made by Cendrine Tourette, PhD in Neuroscience and Director of translational and clinical research projects on neuromuscular diseases at Biophytis.
  • Ms. Tourette also took part in a round table discussion with top-notch experts on new trials and recent results in the treatment of sarcopenia and cachexia.
  • Sarconeos (BIO101) would therefore be the first and only drug candidate to enter Phase 3 for the treatment of sarcopenia.

Biophytis presents the development of Sarconeos (BIO101) in Phase 3 for the treatment of Sarcopenia at the 15th SCWD International Congress

Retrieved on: 
Monday, June 27, 2022
Review, FDA, Ageing, Patient, CEO, Cachexia, Euronext Growth, International, Ticker, ADS, Society, Degenerative disease, COVID-19, Company, Disease, AMF, Society on Sarcopenia, Cachexia and Wasting Disorders, DMD, CET, Forward-looking statement, Duchenne muscular dystrophy, U.S. Securities and Exchange Commission, Hope, PRO, EMA, Risk, Therapy, CTA, LIFE, Clinical trial, Parallel Walk Test, American depositary receipt, SARA, HGS, SEC, Congress, DRS, Shear strength, Outline, Adapted automobile, Patient-reported outcome, Security (finance), Pharmaceutical industry, Medical device, Health insurance, Sarcopenia, European, Nasdaq

Sarconeos (BIO101) has the potential to be the first drug candidate ever moving into Phase 3 in Sarcopenia.

Key Points: 
  • Sarconeos (BIO101) has the potential to be the first drug candidate ever moving into Phase 3 in Sarcopenia.
  • The design of this study may however evolve depending on the discussions currently underway with the European and American health authorities.
  • Sarconeos (BIO101), our leading drug candidate, is a small molecule, administered orally,) just achieved its phase 2 development as a treatment for sarcopenia in the United States and Europe (SARA-INT).
  • A pediatric formulation of Sarconeos (BIO101) is being developed for the treatment of Duchenne Muscular Dystrophy (DMD).

Results of Biophytis SARA-INT Phase 2 Trial with Sarconeos (BIO101) in Sarcopenia will be Released by August 2021

Retrieved on: 
Wednesday, June 30, 2021
Health, Clinical research, Medical statistics, Medical specialties, Clinical trials, Food and Drug Administration, Pharmaceutical industry, Clinical endpoint, Sarcopenia, Society on Sarcopenia, Cachexia and Wasting Disorders

The full results with complete details will be presented during the digital ICSFR scientific & medical conference, next September 29-October 2 2021.

Key Points: 
  • The full results with complete details will be presented during the digital ICSFR scientific & medical conference, next September 29-October 2 2021.
  • The primary endpoint of SARA-INT is patients mobility disability as measured by the gait-speed over the 400-meter walk test (400MWT).
  • Sarconeos (BIO101), our leading drug candidate, is a small molecule, administered orally, being developed as a treatment for sarcopenia in a Phase 2 clinical trial in the United States and Europe (SARA-INT).
  • These forward-looking statements include statements regarding Biophytis anticipated timing for its various Sarconeos (BIO101) clinical trials and expectations regarding commercialization.

Global Cachexia Disease Clinical Trials Review, H2 2020 Edition Featuring 10 Companies & Respective Trials - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 14, 2021
Pharmaceutical, Health, Oncology, Clinical trials, Health sciences, Health, Medicine, Pharmaceutical industry, Clinical research, Clinical trials, Drug discovery, Cachexia, Society on Sarcopenia, Cachexia and Wasting Disorders

b'The "Cachexia Disease - Global Clinical Trials Review, H2, 2020" clinical trials has been added to ResearchAndMarkets.com\'s offering.\n"Cachexia Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Cachexia Clinical trials scenario.

Key Points: 
  • b'The "Cachexia Disease - Global Clinical Trials Review, H2, 2020" clinical trials has been added to ResearchAndMarkets.com\'s offering.\n"Cachexia Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Cachexia Clinical trials scenario.
  • This report provides top line data relating to the clinical trials on Cachexia.\nReport includes an overview of trial numbers and their average enrollment in top countries conducted across the globe.
  • The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.
  • Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).\nReport provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status\nThe report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company\nThe report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment\nAids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials\nFacilitates clinical trial assessment of the indication on a global, regional and country level\n'

Global Cancer Anorexia-Cachexia Syndrome Disease Clinical Trials Review, H2 2020 Edition Featuring 10 Key Players & Their Respective Trials - ResearchAndMarkets.com

Retrieved on: 
Monday, April 12, 2021
General Health, Health, Pharmaceutical, Clinical trials, Oncology, Health sciences, Health, Medicine, Rehabilitation medicine, Pharmaceutical industry, Clinical pharmacology, Cachexia, Geriatrics, Clinical trial, Society on Sarcopenia, Cachexia and Wasting Disorders

b'The "Cancer Anorexia-Cachexia Syndrome Disease - Global Clinical Trials Review, H2, 2020" clinical trials has been added to ResearchAndMarkets.com\'s offering.\n"Cancer Anorexia-Cachexia Syndrome Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Cancer Anorexia-Cachexia Syndrome Clinical trials scenario.\nThis report provides top line data relating to the clinical trials on Cancer Anorexia-Cachexia Syndrome.

Key Points: 
  • b'The "Cancer Anorexia-Cachexia Syndrome Disease - Global Clinical Trials Review, H2, 2020" clinical trials has been added to ResearchAndMarkets.com\'s offering.\n"Cancer Anorexia-Cachexia Syndrome Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Cancer Anorexia-Cachexia Syndrome Clinical trials scenario.\nThis report provides top line data relating to the clinical trials on Cancer Anorexia-Cachexia Syndrome.
  • Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe.
  • The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.
  • Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).\nReport provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status\nThe report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company\nThe report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment\nAids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials\nFacilitates clinical trial assessment of the indication on a global, regional and country level\n'

Akoya’s CODEX® System Utilized in Novel Study of Muscle Strength and Aging Published in Science

Retrieved on: 
Friday, December 11, 2020
Research, Genetics, Stem cells, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, Branches of biology, Medical specialties, Clinical medicine, Rehabilitation medicine, Geriatrics, Muscular system, Exercise physiology, Aging-associated diseases, Sarcopenia, Muscle, Muscle atrophy, Society on Sarcopenia, Cachexia and Wasting Disorders

This study represents the first demonstration of the CODEX system in imaging muscle tissues.

Key Points: 
  • This study represents the first demonstration of the CODEX system in imaging muscle tissues.
  • Muscle loss due to aging, called sarcopenia, is estimated to cost the US healthcare system billions of dollars each year, and results in a reduced quality of life for patients.
  • Dr. Blau and her team are experts in investigating mechanisms of muscle structure and function related to aging and muscle disorders.
  • By blocking the activity of 15-PGDH in old mice, physical strength and muscle mass were restored in the animals.

Global Clinical Trial Pipeline for Chronic Obstructive Pulmonary Disease 2020-2025 - ResearchAndMarkets.com

Retrieved on: 
Friday, April 24, 2020
Health, Clinical trials, Health, Drug discovery, Clinical research, Clinical trial, Design of experiments, Pharmaceutical industry, Biotie Therapies, Society on Sarcopenia, Cachexia and Wasting Disorders

The "Global Chronic Obstructive Pulmonary Disease Clinical Trial Pipeline Highlights - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Chronic Obstructive Pulmonary Disease Clinical Trial Pipeline Highlights - 2020" report has been added to ResearchAndMarkets.com's offering.
  • This report provides the most up-to-date information on key pipeline products in the global Chronic Obstructive Pulmonary Disease market.
  • It covers emerging therapies for Chronic Obstructive Pulmonary Disease in active clinical development stages including early and late-stage clinical trials.
  • The report provides Chronic Obstructive Pulmonary Disease pipeline products by clinical trial stages including both early and late-stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Sarcopenia, H1 2020 - Armgo Pharma Inc, Elevian Inc, Immusoft Corp, Neurotune AG & Ridgeline Therapeutics LLC - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 19, 2020
Pharmaceutical, Health, Clinical trials, Medical specialties, Medicine, Aging-associated diseases, Health, Geriatrics, Rehabilitation medicine, Sarcopenia, Senescence, Society on Sarcopenia, Cachexia and Wasting Disorders

The latest Pharmaceutical and Healthcare disease pipeline guide Sarcopenia - Pipeline Review, H1 2020, provides an overview of the Sarcopenia (Musculoskeletal Disorders) pipeline landscape.

Key Points: 
  • The latest Pharmaceutical and Healthcare disease pipeline guide Sarcopenia - Pipeline Review, H1 2020, provides an overview of the Sarcopenia (Musculoskeletal Disorders) pipeline landscape.
  • The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
  • The Sarcopenia (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Sarcopenia and features dormant and discontinued projects.
  • The pipeline guide reviews key companies involved in Sarcopenia (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.

Chronic Obstructive Pulmonary Disease Clinical Trial Pipeline Highlights 2019 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 11, 2019
Health, General Health, Health, Drug discovery, Clinical pharmacology, Clinical trial, Design of experiments, Pharmaceutical industry, Biotie Therapies, Society on Sarcopenia, Cachexia and Wasting Disorders

The "Global Chronic Obstructive Pulmonary Disease Clinical Trial Pipeline Highlights - 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Chronic Obstructive Pulmonary Disease Clinical Trial Pipeline Highlights - 2019" report has been added to ResearchAndMarkets.com's offering.
  • Chronic Obstructive Pulmonary Disease Pipeline Highlights 2019, provides most up-to-date information on key pipeline products in the global Chronic Obstructive Pulmonary Disease market.
  • It covers emerging therapies for Chronic Obstructive Pulmonary Disease in active clinical development stages including early and late stage clinical trials.
  • The report provides Chronic Obstructive Pulmonary Disease pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Investigators Present Hundreds of Studies to Annual Gathering of Kidney Health Professionals at NKF 2019 Spring Clinical Meetings

Retrieved on: 
Thursday, May 9, 2019
Anatomy, Medicine, Health, RTT, National Kidney Foundation, Kidney diseases, Organ failure, Chronic kidney disease, Kidney, Diabetes mellitus, UK National Kidney Federation, Society on Sarcopenia, Cachexia and Wasting Disorders

NEW YORK, May 9, 2019 /PRNewswire/ -- Investigators from around the country presented hundreds of studies about kidney health and chronic kidney disease during the National Kidney Foundation's 2019 Spring Clinical Meetings in Boston, May 8-12.

Key Points: 
  • NEW YORK, May 9, 2019 /PRNewswire/ -- Investigators from around the country presented hundreds of studies about kidney health and chronic kidney disease during the National Kidney Foundation's 2019 Spring Clinical Meetings in Boston, May 8-12.
  • The event is a chance for investigators to share their findings with more than 3,000 kidney healthcare professionals who attend the annual conference.
  • The study "Prevalence and Factors Associated with Undiagnosed Chronic Kidney Disease in Diabetes Mellitus" was presented to the professional community during the National Kidney Foundation's 2019 Spring Clinical Meetings in Boston this week.
  • The NKF Spring Clinical Meetings are designed for meaningful change in the multidisciplinary healthcare teams' skills, performance, and patient health outcomes.